Neurosense Therapeutics Stock Performance
| NRSN Stock | USD 0.92 0.07 7.07% |
On a scale of 0 to 100, Neurosense Therapeutics holds a performance score of 4. The company secures a Beta (Market Risk) of 1.63, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurosense Therapeutics will likely underperform. Please check Neurosense Therapeutics' downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Neurosense Therapeutics' current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Neurosense Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Neurosense Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification | 08/30/2024 |
2 | NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimers | 09/24/2024 |
3 | NeuroSense Therapeutics Ltd. Sees Significant Decrease in Short Interest | 10/14/2024 |
4 | New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients | 10/24/2024 |
5 | NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission | 10/28/2024 |
| Begin Period Cash Flow | 3.5 M |
Neurosense |
Neurosense Therapeutics Relative Risk vs. Return Landscape
If you would invest 81.00 in Neurosense Therapeutics on August 24, 2024 and sell it today you would earn a total of 11.00 from holding Neurosense Therapeutics or generate 13.58% return on investment over 90 days. Neurosense Therapeutics is currently generating 0.3478% in daily expected returns and assumes 5.5091% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Neurosense, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurosense Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurosense Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurosense Therapeutics, and traders can use it to determine the average amount a Neurosense Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0631
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NRSN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.51 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.35 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Neurosense Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurosense Therapeutics by adding it to a well-diversified portfolio.
Neurosense Therapeutics Fundamentals Growth
Neurosense Stock prices reflect investors' perceptions of the future prospects and financial health of Neurosense Therapeutics, and Neurosense Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurosense Stock performance.
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 | ||||
| Current Valuation | 18.44 M | ||||
| Shares Outstanding | 19.81 M | ||||
| Price To Book | 4.15 X | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (11.28 M) | ||||
| Cash And Equivalents | 10.37 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 142 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.09 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Earnings Per Share | (0.65) X | ||||
| Market Capitalization | 19.61 M | ||||
| Total Asset | 3.18 M | ||||
| Retained Earnings | (32.07 M) | ||||
| Working Capital | (543 K) | ||||
About Neurosense Therapeutics Performance
By examining Neurosense Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Neurosense Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neurosense Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -17.3 K | -18.2 K | |
| Return On Tangible Assets | (3.18) | (3.34) | |
| Return On Capital Employed | 42.58 | 44.70 | |
| Return On Assets | (3.18) | (3.34) | |
| Return On Equity | 5.39 | 5.66 |
Things to note about Neurosense Therapeutics performance evaluation
Checking the ongoing alerts about Neurosense Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurosense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurosense Therapeutics had very high historical volatility over the last 90 days | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Neurosense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission |
- Analyzing Neurosense Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurosense Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Neurosense Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurosense Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurosense Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurosense Therapeutics' stock. These opinions can provide insight into Neurosense Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.